Ciprofloxacin/fluocinolone acetonide

Drug Profile

Ciprofloxacin/fluocinolone acetonide

Alternative Names: Cetraxal Comp; Cetraxal Plus; DF277/DF289; DF289/DF277; Duoxal; Fluocinolone acetonide/ciprofloxacin; Infalin Duo; Otixal; Otixal®; Otospon; Otovel; OTOVEL; Ultramicina Plus

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SALVAT
  • Developer Arbor Pharmaceuticals; Pediapharm; SALVAT
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 03 Aug 2017 Chemical structure information added
  • 22 Jul 2017 Salvat initiates enrolment in a phase III trial for Otitis Externa (In infants, In children, In adolescents, In adults) in Spain (Otic) (NCT03196973)
  • 29 Jun 2017 Salvat plans a phase III trial for Otitis Externa (In infants, In children, In adolescents, In adults) in Spain, in June 2017 (Otic) (NCT03196973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top